Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

March 2, 2015

Study Completion Date

March 2, 2015

Conditions
Infections, Respiratory Tract
Interventions
DRUG

GSK2140944

GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution

DRUG

GSK2140944 placebo

GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.

DRUG

Moxifloxacin

Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.

DRUG

Moxifloxacin placebo

Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02257398 - Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers | Biotech Hunter | Biotech Hunter